Axsome Therapeutics, Inc. (AXSM) Q4 FY25 Earnings Call

Commercial growth remains strong, while Alzheimer’s agitation approval and multiple pipeline milestones provide additional catalysts [15][16][6].

Q4 FY25 results, source: company transcript and SEC filings
QuarterQ4 FY25
Call date2026-02-23
Length51 minutes
EPS$-0.71
EPS consensus$-0.70
Revenue$171.0M
Revenue consensus$192.8M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q2 FY26 · Q2 FY25

All AXSM earnings · Back to AXSM overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.